NCT03383081View on ClinicalTrials.gov

The Safety/Efficacy of hUC Mesenchymal Stem Cells（19#iSCLife®-OA） Therapy for Patients With Osteoarthritis

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Osteoarthritis, Knee
Interventions
BIOLOGICAL

Low dose mesenchymal stem cells

Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);

BIOLOGICAL

High dose mesenchymal stem cells

Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)

PROCEDURE

Intraarticular injection

Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group

Trial Locations (1)

410008

RECRUITING

Xiangya Hospital Central South University, Changsha

All Listed Sponsors
lead

Sclnow Biotechnology Co., Ltd.

INDUSTRY